Recursion’s REC-994 Trial Fully Enrolled

Breaking News: Recursion's Phase 2 Trial for the Treatment of Cavernous Malformation has Fully EnrolledWe are thrilled to announce that the Phase 2 safety trial of Recursion’s REC-994 medicine, being developed specifically for symptomatic CCM, has fully enrolled 60 patients ahead of schedule.

Our thanks to all of our members who are participating in this first-ever industry-sponsored trial. You made this enrollment a success, and we are so proud of you for your commitment and courage.

Read the Recursion press release.